Noven Appoints Fred G. Weiss to Board of Directors
Business Wire - October 07, 1997 08:12
MIAMI--(BUSINESS WIRE)--Oct. 7, 1997--Noven Pharmaceuticals Inc. (NASDAQ:NOVN) announced Tuesday the appointment of Fred G. Weiss as a member of the board of directors.
Weiss retired from Warner-Lambert Co. last year, where he attained the positions of vice president and treasurer and most recently vice president, Planning, Investment and Development. He joined Warner-Lambert in 1979.
While at Warner-Lambert, Weiss reported to the chairman/CEO, and was a member of the Management Committee, and was directly responsible for Warner-Lambert's investments. Weiss played a central role in negotiating over 50 worldwide transactions for Warner-Lambert in all its business sectors. These have included both the sale and acquisition of businesses and the establishment of joint ventures.
Weiss was a member of the boards of the Glaxo Wellcome/Warner-Lambert OTC Joint Venture and Warner-Chilcott plc, a privately held generic drug company. He was also the president of MedTech Ventures Inc., Warner-Lambert's venture capital subsidiary. Weiss was the primary senior executive responsible for the management of the assets of Warner-Lambert's employee benefit plan. In the U.S., these plan assets exceeded $2 billion at the end of 1996.
Steven Sablotsky, Noven's president and chairman of the board said, "Mr. Weiss is an outstanding addition to our board. He has a broad range of experience in the pharmaceutical industry and we look forward to his contributions."
Noven Pharmaceuticals Inc. is an industry leader in the development and commercialization of advanced drug delivery systems.
Forward looking statements contained herein are qualified by and subject to the risks and uncertainties specified by Noven in its most recent periodic filings with the Securities and Exchange Commission.
CONTACT: Noven Pharmaceuticals
Mitchell Goldberg, 516/739-0536 |
